Detailed Information

Cited 2 time in webofscience Cited 5 time in scopus
Metadata Downloads

Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysisopen access

Authors
Lee, Byung SeokSong, Myeong JunKwon, Jung HyunLee, Tae HeeJang, Ji WoongKim, Seok HyunLee, Sae HwanKim, Hong SooKim, Ji HoonKim, Seok BaeKo, Soon YoungSong, Do Seon
Issue Date
Mar-2019
Publisher
EDITORIAL OFFICE GUT & LIVER
Keywords
Daclatasvir; Asunaprevir; Chronic hepatitis C virus; Hemodialysis; Sustained virologic response
Citation
GUT AND LIVER, v.13, no.2, pp.191 - 196
Indexed
SCIE
SCOPUS
KCI
Journal Title
GUT AND LIVER
Volume
13
Number
2
Start Page
191
End Page
196
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/2331
DOI
10.5009/gnl18240
ISSN
1976-2283
Abstract
Background/Aims: We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods: We performed a single-arm, multicenter prospective study. Twenty-one chronic hemodialysis patients with HCV infection were prospectively enrolled from February 2016 to April 2017. We evaluated the virological responses at weeks 4, 12, and 24 (end of treatment [EOT]) and the sustained virological response at 12 weeks after the EOT (SVR12). The tolerability and safety of the drugs were also assessed. Results: None of the 20 patients had the NS5A resistance-associated variant (NS5A RAV), and one patient was indeterminate for the NS5A RAV. Seventeen patients (80%) completed the 24 weeks of treatment with DCV and ASV. Four patients discontinued the study prior to week 12. In an intention-to-treat analysis, the SVR12 was 76.1%. In a per-protocol analysis, patients who completed DCV and ASV treatment achieved an SVR12 of 100%. DCV and ASV were well tolerated by the majority of patients. Three patients discontinued treatment due to adverse events (AEs) including dizziness, dyspnea, and neutropenia. The patient with indeterminate NS5A RAV showed viral breakthrough and discontinued treatment. Conclusions: DCV and ASV combination therapy in chronic hemodialysis patients with HCV infection achieved a high SVR12 rate with few AEs. To maximize the SVR12 rate, it is important to identify candidates by baseline RAV testing Close monitoring of the safety and tolerability of DCV and ASV may be necessary in HCV-infected patients on hemodialysis.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Ji Hoon photo

Kim, Ji Hoon
구로병원 (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE